Labcorp Acquires Personal Genome Diagnostics (PGDx)

LabGenomics USA LLC Acquires QDx Pathology

September 5, 2023

Healthcare Services

LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Kindbody Acquires Phosphorus Labs

June 7, 2022

Biotechnology

Kindbody has acquired Phosphorus Labs, a preventative genomics and clinical genetic-testing company, including Phosphorus’s 8,000 sq. ft. reference laboratory in Secaucus, New Jersey. The acquisition brings genetic testing and carrier screening capabilities in-house as Kindbody creates its KindLabs division to integrate diagnostics into its end-to-end fertility and family-building care.

LabCorp Acquires MNG Laboratories from HealthEdge

March 4, 2019

Healthcare Services

LabCorp has acquired MNG Laboratories, an Atlanta-based clinical diagnostic provider specializing in neurogenetics and next-generation sequencing, from HealthEdge Investment Partners' Fund II. The acquisition expands LabCorp’s neurology and neurogenetics testing capabilities and makes MNG’s testing services available through LabCorp’s Covance drug development business.

Quest Diagnostics Acquires Haystack Oncology

April 27, 2023

Healthcare Services

Quest Diagnostics has agreed to acquire Haystack Oncology in an all-cash transaction valued at $300 million at closing plus up to $150 million in potential milestones. The acquisition adds Haystack's sensitive ctDNA-based minimal residual disease (MRD) liquid biopsy technology to Quest's oncology, genomics and pathology capabilities to expand clinical lab services for MRD testing beginning in 2024.

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.